Loading...

Henry Chambers, III, MD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentMedicine
Address1001 Potrero Ave
San Francisco CA 94110
Phone415-206-5437
vCardDownload vCard
    Other Positions
    TitleChief, Division of Infectious Diseases, SFGH

    TitleDirector, Clinical Research Services, CTSI


    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency School of Medicine
    Vanderbilt UniversityM.D.School of Medicine
    Centre College Kentucky B.A.

    Collapse Overview 
    Collapse Overview
    Dr. Chambers clinical and research interests are antimicrobial drug resistance, staphylococcal infections, experimental therapeutics, and epidemiology and pathogenesis of disease caused by Staphylococcus aureus. He is editor for the Sanford Guide to Antimicrobial Therapy and he has over 200 original publications and textbook chapters in the areas of drug resistance, endocarditis, bacterial infections, and staphylococcal diseases.

    Dr. Chambers received his BA from Centre College in Kentucky and is a graduate of the Vanderbilt University School of Medicine. He trained in Internal Medicine and Infectious Diseases at the University of California San Francisco. Dr. Chambers has been a member of the medical faculty of the UCSF since 1983 where he currently is Professor of Medicine, Medical Director of Clinical Research Services for CTSI. He is an editor for Antimicrobial Agents and Chemotherapy, a reviewer for numerous medical publications, a peer reviewer for NIH study sections.


    Collapse Research 
    Collapse Research Activities and Funding
    Antibacterial Resistance Leadership Group (ARLG)
    NIH/NIAID UM1AI104681Jun 1, 2013 - Nov 30, 2019
    Role: Co-Principal Investigator
    Novel Mechanisms of Beta-lactam Resistance in Staph Aureus
    NIH/NIAID R01AI100291Aug 1, 2012 - Dec 31, 2022
    Role: Principal Investigator
    Novel Mechanisms of Beta-lactam Resistance in Staph Aureus
    NIH/NIAID R56AI100291Aug 1, 2012 - Jul 31, 2018
    Role: Principal Investigator
    Genetic Basis of Virulence of Community MRSA Clone USA300
    NIH/NIAID R01AI070289Apr 1, 2008 - Mar 31, 2012
    Role: Principal Investigator
    Gordon Research Conference on Staphylococcal Diseases
    NIH/NIAID R13AI050556Jul 1, 2001 - Jun 30, 2002
    Role: Principal Investigator
    Biology of Infectious Diseases Training Program
    NIH/NIAID T32AI007641Aug 1, 2000 - Aug 31, 2022
    Role: Principal Investigator
    PENICILLIN INTERACTIVE PROTEINS OF STAPHYLOCOCCUS AUREUS
    NIH/NIAID R01AI046610Feb 1, 2000 - Jan 31, 2005
    Role: Principal Investigator
    GORDON CONFERENCE ON STAPHYLOCOCCAL DISEASES
    NIH/NIAID R13AI043943May 1, 1999 - Apr 30, 2000
    Role: Principal Investigator
    VANCOMYCIN-RESISTANT STAPHYLOCOCCUS AUREUS
    NIH/NIAID R03AI043959Apr 1, 1999 - Mar 31, 2002
    Role: Principal Investigator
    PENICILLIN BINDING PROTEINS OF STAPHYLOCOCCUS AUREUS
    NIH/NIAID R21AI032496Sep 30, 1996 - Sep 29, 1999
    Role: Principal Investigator
    DEVELOPMENT OF DRUGS FOR TREATING TUBERCULOSIS
    NIH/NIAID R01AI033702Sep 30, 1992 - Aug 31, 1997
    Role: Principal Investigator
    METHICILLIN RESISTANCE OF STAPHYLOCOCCUS AUREUS
    NIH/NIAID R29AI027406Dec 1, 1988 - Nov 30, 1993
    Role: Principal Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000083Oct 1, 1974 - Nov 30, 2007
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Global Health
    Collapse Websites
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. da Costa TM, de Oliveira CR, Chambers HF, Chatterjee SS. PBP4: A New Perspective on Staphylococcus aureus ß-Lactam Resistance. Microorganisms. 2018 Jun 22; 6(3). PMID: 29932109.
      View in: PubMed
    2. Doernberg SB, Abbo LM, Burdette SD, Fishman NO, Goodman EL, Kravitz GR, Leggett JE, Moehring RW, Newland JG, Robinson PA, Spivak ES, Tamma PD, Chambers HF. Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting. Clin Infect Dis. 2018 Mar 26. PMID: 29590355.
      View in: PubMed
    3. Basuino L, Jousselin A, Alexander JAN, Strynadka NCJ, Pinho MG, Chambers HF, Chatterjee SS. PBP4 activity and its overexpression are necessary for PBP4-mediated high-level ß-lactam resistance. J Antimicrob Chemother. 2018 Jan 19. PMID: 29360990.
      View in: PubMed
    4. Katayama Y, Azechi T, Miyazaki M, Takata T, Sekine M, Matsui H, Hanaki H, Yahara K, Sasano H, Asakura K, Takaku T, Ochiai T, Komatsu N, Chambers HF. Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2017 Nov; 61(11). PMID: 28827421.
      View in: PubMed
    5. Chatterjee SS, Chen L, Gilbert A, da Costa TM, Nair V, Datta SK, Kreiswirth BN, Chambers HF. PBP4 Mediates ß-Lactam Resistance by Altered Function. Antimicrob Agents Chemother. 2017 Nov; 61(11). PMID: 28807923.
      View in: PubMed
    6. Doernberg SB, Chambers HF. Antimicrobial Stewardship Approaches in the Intensive Care Unit. Infect Dis Clin North Am. 2017 09; 31(3):513-534. PMID: 28687210.
      View in: PubMed
    7. Daum RS, Miller LG, Immergluck L, Fritz S, Creech CB, Young D, Kumar N, Downing M, Pettibone S, Hoagland R, Eells SJ, Boyle MG, Parker TC, Chambers HF. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. N Engl J Med. 2017 06 29; 376(26):2545-2555. PMID: 28657870.
      View in: PubMed
    8. Hamilton SM, Alexander JAN, Choo EJ, Basuino L, da Costa TM, Severin A, Chung M, Aedo S, Strynadka NCJ, Tomasz A, Chatterjee SS, Chambers HF. High-Level Resistance of Staphylococcus aureus to ß-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4). Antimicrob Agents Chemother. 2017 06; 61(6). PMID: 28373193.
      View in: PubMed
    9. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. Can Ceftazidime-Avibactam and Aztreonam Overcome ß-Lactam Resistance Conferred by Metallo-ß-Lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017 04; 61(4). PMID: 28167541.
      View in: PubMed
    10. Chambers HF, Cross HR, Evans SR, Kreiswirth BN, Fowler VG. The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress. Clin Infect Dis. 2017 Mar 15; 64(suppl_1):S3-S7. PMID: 28350896.
      View in: PubMed
    11. Nigo M, Diaz L, Carvajal LP, Tran TT, Rios R, Panesso D, Garavito JD, Miller WR, Wanger A, Weinstock G, Munita JM, Arias CA, Chambers HF. Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis. Antimicrob Agents Chemother. 2017 03; 61(3). PMID: 28232309.
      View in: PubMed
    12. Choo EJ, Chambers HF. Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Infect Chemother. 2016 Dec; 48(4):267-273. PMID: 28032484.
      View in: PubMed
    13. Diep BA, Le VT, Badiou C, Le HN, Pinheiro MG, Duong AH, Wang X, Dip EC, Aguiar-Alves F, Basuino L, Marbach H, Mai TT, Sarda MN, Kajikawa O, Matute-Bello G, Tkaczyk C, Rasigade JP, Sellman BR, Chambers HF, Lina G. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci Transl Med. 2016 09 21; 8(357):357ra124. PMID: 27655850.
      View in: PubMed
    14. Baxi SM, Clemenzi-Allen A, Gahbauer A, Deck D, Imp B, Vittinghoff E, Chambers HF, Doernberg S. Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2016 09; 60(9):5276-84. PMID: 27324762; PMCID: PMC4997864 [Available on 03/01/17].
    15. Chambers HF, Basuino L, Hamilton SM, Choo EJ, Moise P. Daptomycin-ß-Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Endocarditis. Antimicrob Agents Chemother. 2016 07; 60(7):3976-9. PMID: 27090173; PMCID: PMC4914634 [Available on 01/01/17].
    16. Chan LC, Gilbert A, Basuino L, da Costa TM, Hamilton SM, Dos Santos KR, Chambers HF, Chatterjee SS. PBP 4 Mediates High-Level Resistance to New-Generation Cephalosporins in Staphylococcus aureus. Antimicrob Agents Chemother. 2016 07; 60(7):3934-41. PMID: 27067335; PMCID: PMC4914628 [Available on 01/01/17].
    17. Greninger AL, Chatterjee SS, Chan LC, Hamilton SM, Chambers HF, Chiu CY. Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance. PLoS One. 2016; 11(2):e0149541. PMID: 26890675; PMCID: PMC4758708.
    18. Chan LC, Basuino L, Dip EC, Chambers HF. Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2015; 59(6):3252-6. PMID: 25801564; PMCID: PMC4432129.
    19. Miller LG, Daum RS, Creech CB, Young D, Downing MD, Eells SJ, Pettibone S, Hoagland RJ, Chambers HF. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med. 2015 Mar 19; 372(12):1093-103. PMID: 25785967; PMCID: PMC4547538.
    20. Chan LC, Basuino L, Diep B, Hamilton S, Chatterjee SS, Chambers HF. Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2015 May; 59(5):2960-3. PMID: 25753637; PMCID: PMC4394828.
    21. Chambers HF. Probability of eradication using vancomycin alone or in combination for methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2014 Dec; 58(12):7617. PMID: 25392536; PMCID: PMC4249517.
    22. Chambers HF. Pharmacology and the treatment of complicated skin and skin-structure infections. N Engl J Med. 2014 Jun 05; 370(23):2238-9. PMID: 24897088.
      View in: PubMed
    23. Chambers HF, Bartlett JG, Bonomo RA, Chiou C, Cosgrove SE, Cross HR, Daum RS, Downing M, Evans SR, Knisely J, Kreiswirth BN, Lautenbach E, Mickley BS, Patel R, Pettigrew MM, Rodvold KA, Spellberg B, Fowler VG. Antibacterial resistance leadership group: open for business. Clin Infect Dis. 2014 Jun; 58(11):1571-6. PMID: 24610430; PMCID: PMC4017892.
    24. Date SV, Modrusan Z, Lawrence M, Morisaki JH, Toy K, Shah IM, Kim J, Park S, Xu M, Basuino L, Chan L, Zeitschel D, Chambers HF, Tan MW, Brown EJ, Diep BA, Hazenbos WL. Global gene expression of methicillin-resistant Staphylococcus aureus USA300 during human and mouse infection. J Infect Dis. 2014 May 15; 209(10):1542-50. PMID: 24286981.
      View in: PubMed
    25. Diep BA, Afasizheva A, Le HN, Kajikawa O, Matute-Bello G, Tkaczyk C, Sellman B, Badiou C, Lina G, Chambers HF. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis. 2013 Jul; 208(1):75-82. PMID: 23532096; PMCID: PMC3666136.
    26. Hsiang MS, Shiau R, Nadle J, Chan L, Lee B, Chambers HF, Pan E. Epidemiologic Similarities in Pediatric Community-Associated Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus in the San Francisco Bay Area. J Pediatric Infect Dis Soc. 2012 Sep; 1(3):200-11. PMID: 23687577; PMCID: PMC3656541.
    27. Tattevin P, Schwartz BS, Graber CJ, Volinski J, Bhukhen A, Bhukhen A, Mai TT, Vo NH, Dang DN, Phan TH, Basuino L, Perdreau-Remington F, Chambers HF, Diep BA. Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2012 Sep; 55(6):781-8. PMID: 22670044; PMCID: PMC3657511.
    28. Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis. 2012 Sep; 55(5):615-20. PMID: 22563022; PMCID: PMC3491851.
    29. Gardete S, Kim C, Hartmann BM, Mwangi M, Roux CM, Dunman PM, Chambers HF, Tomasz A. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog. 2012 Feb; 8(2):e1002505. PMID: 22319446; PMCID: PMC3271070.
    30. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011 Feb 01; 52(3):285-92. PMID: 21217178.
      View in: PubMed
    31. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011 Feb 01; 52(3):e18-55. PMID: 21208910.
      View in: PubMed
    32. Banerjee R, Gretes M, Harlem C, Basuino L, Chambers HF. A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level ß-lactam resistance contains mutations in three genes. Antimicrob Agents Chemother. 2010 Nov; 54(11):4900-2. PMID: 20805396; PMCID: PMC2976154.
    33. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, Gardner DJ, Fan X, Tseng CW, Liu GY, Badiou C, Etienne J, Lina G, Matthay MA, DeLeo FR, Chambers HF. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A. 2010 Mar 23; 107(12):5587-92. PMID: 20231457; PMCID: PMC2851770.
    34. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated meticillin-resistant Staphylococcus aureus. Lancet. 2010 May 01; 375(9725):1557-68. PMID: 20206987.
      View in: PubMed
    35. Mendes RE, Sader HS, Deshpande LM, Diep BA, Chambers HF, Jones RN. Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid. J Clin Microbiol. 2010 Feb; 48(2):568-74. PMID: 19940054; PMCID: PMC2815625.
    36. DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest. 2009 Sep; 119(9):2464-74. PMID: 19729844; PMCID: PMC2735934.
    37. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009 Sep; 7(9):629-41. PMID: 19680247; PMCID: PMC2871281.
    38. Winston L, Chambers H. Coming home with MRSA. Arch Intern Med. 2009 Aug 10; 169(15):1379-80. PMID: 19667300.
      View in: PubMed
    39. Schwartz BS, Graber CJ, Diep BA, Basuino L, Perdreau-Remington F, Chambers HF. Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300. Clin Infect Dis. 2009 May 15; 48(10):1483-4. PMID: 19374563.
      View in: PubMed
    40. Tattevin P, Basuino L, Chambers HF. Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response. Res Microbiol. 2009 Apr; 160(3):187-92. PMID: 19366630.
      View in: PubMed
    41. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR, Chambers HF, Lu Y, Otto M. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A. 2009 Apr 07; 106(14):5883-8. PMID: 19293374; PMCID: PMC2667066.
    42. Cosgrove SE, Vigliani GA, Fowler VG, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009 Mar 15; 48(6):713-21. PMID: 19207079.
      View in: PubMed
    43. Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic. J Acquir Immune Defic Syndr. 2008 Oct 01; 49(2):231-3. PMID: 18820536.
      View in: PubMed
    44. Diep BA, Palazzolo-Ballance AM, Tattevin P, Basuino L, Braughton KR, Whitney AR, Chen L, Kreiswirth BN, Otto M, DeLeo FR, Chambers HF. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS One. 2008 Sep 12; 3(9):e3198. PMID: 18787708; PMCID: PMC2527530.
    45. Liu C, Graber CJ, Karr M, Diep BA, Basuino L, Schwartz BS, Enright MC, O'Hanlon SJ, Thomas JC, Perdreau-Remington F, Gordon S, Gunthorpe H, Jacobs R, Jensen P, Leoung G, Rumack JS, Chambers HF. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin Infect Dis. 2008 Jun 01; 46(11):1637-46. PMID: 18433335.
      View in: PubMed
    46. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008 Jun 01; 46 Suppl 5:S368-77. PMID: 18462092.
      View in: PubMed
    47. Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, des Etages SA, Jones A, Palazzolo-Ballance AM, Perdreau-Remington F, Sensabaugh GF, DeLeo FR, Chambers HF. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J Infect Dis. 2008 Jun 01; 197(11):1523-30. PMID: 18700257.
      View in: PubMed
    48. Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008 Jun; 52(6):2089-96. PMID: 18378703; PMCID: PMC2415812.
    49. David MZ, Siegel JD, Chambers HF, Daum RS. Determining whether methicillin-resistant Staphylococcus aureus is associated with health care. JAMA. 2008 Feb 06; 299(5):519; author reply 519-20. PMID: 18252879.
      View in: PubMed
    50. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008 Feb 19; 148(4):249-57. PMID: 18283202.
      View in: PubMed
    51. Rajendran PM, Young D, Maurer T, Chambers H, Perdreau-Remington F, Ro P, Harris H. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2007 Nov; 51(11):4044-8. PMID: 17846141; PMCID: PMC2151464.
    52. Chambers HF, Hegde SS. Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin? Expert Rev Anti Infect Ther. 2007 Jun; 5(3):333-5. PMID: 17547497.
      View in: PubMed
    53. Graber CJ, Wong MK, Carleton HA, Perdreau-Remington F, Haller BL, Chambers HF. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg Infect Dis. 2007 Mar; 13(3):491-3. PMID: 17552110; PMCID: PMC2725904.
    54. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006 Aug 17; 355(7):653-65. PMID: 16914701.
      View in: PubMed
    55. Rutar T, Chambers HF, Crawford JB, Perdreau-Remington F, Zwick OM, Karr M, Diehn JJ, Cockerham KP. Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant Staphylococcus aureus. Ophthalmology. 2006 Aug; 113(8):1455-62. PMID: 16766029.
      View in: PubMed
    56. Seeley EJ, Chambers HF. Diabetic ketoacidosis precipitated by Staphylococcus aureus abscess and bacteremia due to acupuncture: case report and review of the literature. Clin Infect Dis. 2006 Jul 01; 43(1):e6-8. PMID: 16758409.
      View in: PubMed
    57. Madrigal AG, Basuino L, Chambers HF. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2005 Aug; 49(8):3163-5. PMID: 16048918; PMCID: PMC1196289.
    58. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother. 2005 Jul; 49(7):2816-21. PMID: 15980354; PMCID: PMC1168716.
    59. Eguia JM, Liu C, Moore M, Wrone EM, Pont J, Gerberding JL, Chambers HF. Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area. Clin Infect Dis. 2005 Jun 01; 40(11):1617-24. PMID: 15889359.
      View in: PubMed
    60. Siboo IR, Chambers HF, Sullam PM. Role of SraP, a Serine-Rich Surface Protein of Staphylococcus aureus, in binding to human platelets. Infect Immun. 2005 Apr; 73(4):2273-80. PMID: 15784571; PMCID: PMC1087419.
    61. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2005 Mar; 49(3):884-8. PMID: 15728879; PMCID: PMC549268.
    62. Winston LG, Charlebois ED, Pang S, Bangsberg DR, Perdreau-Remington F, Chambers HF. Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci. Am J Infect Control. 2004 Dec; 32(8):462-9. PMID: 15573053.
      View in: PubMed
    63. Young DM, Harris HW, Charlebois ED, Chambers H, Campbell A, Perdreau-Remington F, Lee C, Mankani M, Mackersie R, Schecter WP. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg. 2004 Sep; 139(9):947-51; discussion 951-3. PMID: 15381611.
      View in: PubMed
    64. Wilke MS, Hills TL, Zhang HZ, Chambers HF, Strynadka NC. Crystal structures of the Apo and penicillin-acylated forms of the BlaR1 beta-lactam sensor of Staphylococcus aureus. J Biol Chem. 2004 Nov 05; 279(45):47278-87. PMID: 15322076.
      View in: PubMed
    65. Charlebois ED, Perdreau-Remington F, Kreiswirth B, Bangsberg DR, Ciccarone D, Diep BA, Ng VL, Chansky K, Edlin BR, Edlin B, Chambers HF. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2004 Jul 01; 39(1):47-54. PMID: 15206052; PMCID: PMC2567833.
    66. Winston LG, Pang S, Haller BL, Wong M, Chambers HF, Perdreau-Remington F. API 20 strep identification system may incorrectly speciate enterococci with low level resistance to vancomycin. Diagn Microbiol Infect Dis. 2004 Apr; 48(4):287-8. PMID: 15062923.
      View in: PubMed
    67. Katayama Y, Zhang HZ, Chambers HF. PBP 2a mutations producing very-high-level resistance to beta-lactams. Antimicrob Agents Chemother. 2004 Feb; 48(2):453-9. PMID: 14742194; PMCID: PMC321522.
    68. Eguia JM, Chambers HF. Community-acquired Methicillin-resistant Staphylococcus aureus: Epidemiology and Potential Virulence Factors. Curr Infect Dis Rep. 2003 Dec; 5(6):459-466. PMID: 14642185.
      View in: PubMed
    69. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother. 2003 Oct; 47(10):3040-5. PMID: 14506006; PMCID: PMC201119.
    70. Katayama Y, Zhang HZ, Hong D, Chambers HF. Jumping the barrier to beta-lactam resistance in Staphylococcus aureus. J Bacteriol. 2003 Sep; 185(18):5465-72. PMID: 12949098; PMCID: PMC193760.
    71. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother. 2003 Apr; 47(4):1262-6. PMID: 12654656; PMCID: PMC152514.
    72. Chambers HF. Solving staphylococcal resistance to beta-lactams. Trends Microbiol. 2003 Apr; 11(4):145-8. PMID: 12706985.
      View in: PubMed
    73. Eguia JM, Chambers HF. Methicillin-resistant staphylococci and their treatment in the intensive care unit. Semin Respir Crit Care Med. 2003 Feb; 24(1):37-48. PMID: 16088523.
      View in: PubMed
    74. Katayama Y, Zhang HZ, Chambers HF. Effect of disruption of Staphylococcus aureus PBP4 gene on resistance to beta-lactam antibiotics. Microb Drug Resist. 2003; 9(4):329-36. PMID: 15000739.
      View in: PubMed
    75. Winston LG, Bangsberg DR, Chambers HF, Felt SC, Rosen JI, Charlebois ED, Wong M, Steele L, Gerberding JL, Perdreau-Remington F. Epidemiology of vancomycin-resistant Enterococcus faecium under a selective isolation policy at an urban county hospital. Am J Infect Control. 2002 Nov; 30(7):400-6. PMID: 12410216.
      View in: PubMed
    76. Charlebois ED, Bangsberg DR, Moss NJ, Moore MR, Moss AR, Chambers HF, Perdreau-Remington F. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis. 2002 Feb 15; 34(4):425-33. PMID: 11797167.
      View in: PubMed